Asfotase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Asfotase Alfa. Educational only — not medical advice.
Labeled uses
STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Source: FDA labeling via NIH DailyMed (set 3387574f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.